8Balakumar P,Arora MK,Ganti SS,et al. Recent advances in pharmacotherapy for diabetic nephropathy: Current perspectives and future directions[ J ]. Pharmacol Res, 2009,60 ( 1 ) : 24 - 32.
9Navarro JF, Mora C, Macia M, et al. Infammatory parameters are independenty associated with nrinary albumin in Type 2 diabeties mellirus[ J ]. Am J Kidney Dis, 2003,42 ( 1 ):53 - 55.
4Brenner BM, Cooper ME, de Zeeuw D,et al.Effects of losar- tanon renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy[J].New Engl J Med,2001,345 (12) : 861-869.
5Mogensen CE.Management of early nephropathy in diabet- ic patients[J].Annu Rev Med, 1995,46(5):79-93.
6Toyama T, Shimizu M, Furuiebi K,et al.Treatment and im- pact of dyslipidemia in diabetic nephropathy[J].Clin Exp Nepbrol, 2014,18 ( 1 ) : 201-205.
7Vupputuri S, Nichols GA, Lau H,et al.Risk of progression of nephropathy in a population-based sample with type 2 di- abetes[J]. Diabetes Res Clin Pract, 2011,91 (2) : 246-252.
